Irving Dark is a biometrics Subject Matter Expert with over 30 years of industry experience guiding drug, biologic, and medical device products successfully through the development process. Currently, he is on the Board of Directors of MMS, Founder/Managing Director of Sun Rock Partners, and an Affiliate Partner at Lindsay Goldberg.

Irving established the Clinical Research Services division at Cytel and served as Senior Vice President of Project Based Services for over 13 years. Prior to Cytel, he held senior leadership roles at Veristat, where he established and oversaw several core business units.

Earlier in his career, Irving held key positions at PAREXEL, where he managed Phase I – III clinical trials in the US, South America, Europe and Asia. Major therapeutic areas of projects included: lipid-lower agent (CRESTOR®), HIV (NELFINAVIR®), acromegaly (SOMATULINE®), and Stroke.

Irving has an in-depth knowledge of clinical development and biometrics, is co-author of numerous published clinical studies, and a DIA invited speaker. Irving holds Bachelor of Arts in Economics from the University of Rhode Island.

Suggested For You

perspectives

October 8th, 2024

Diversity Action Plan Guidance Part I: Implications for Sponsors

webinar

October 22nd, 2024

Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules

perspectives

September 30th, 2024

Meet the Leaders Driving MMS’s European Growth

perspectives

September 30th, 2024

The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry

perspectives

September 24th, 2024

Embracing Quality Management Maturity (QMM) at the Cornerstone of the Pharmaceutical Industry

perspectives

September 11th, 2024

From Historical Precedent to Modern Approvals: Lessons Learned on OTC Drug Products for FDA OMORs

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

perspectives

September 4th, 2024

Email Security – Navigating Through the Process of Validation and Compliance with Healthcare Business Stakeholders

perspectives

August 27th, 2024

Optimizing Oncology Drug Development: FDA Expedited Pathways, Real-Time Review, and Global Programs

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval